Trial Profile
Anlotinib used for advanced intrahepatic cholangiocarcinoma with first-line treatment failure: a single-arm, open, exploratory study
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 27 Sep 2019
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 27 Sep 2019 New trial record